Johnson & Johnson


5 Best Dividend Stocks to Buy Now

There’s no better time than now to invest in dividend stocks.

And some of the best dividend stocks that beat the S&P 500’s average yield of 2.00% can be found in the healthcare sector.

Global dividends fell by 12.2% in 2020 after the pandemic forced businesses and corporations to make a total of $220 billion in dividend cuts between the second and fourth quarters of 2020.

Since then, dividend payments jumped 26% to $471.7 billion.

And dividends paid to investors are expected to pay out $1.39 trillion by the end of the year.

We only have to look at one sector to find the best combination of yields and strong balance sheets.



This Cheap Stock Opens up a $100 Billion Medical Market

Understandably, a lot of the world's medical and scientific firepower was focused on coronavirus vaccines this year.

But other advances in medicine have the potential to do even more for investors than the "vaccine stocks" did.

Shah's looking at a potential $100 billion medical market, and sizing up a $6 stock to play it…



Honest Company Stock: Why You Should Avoid It After the IPO

Honest Company stock almost went public before.

Ironically, a lack of dishonesty put it on hold.

The Honest Company, founded by actress Jessica Alba, billed itself as "clean and sustainable," then it was found not to be so.

Five years later, it will trade on the Nasdaq under the ticker symbol "HNST." The company said on April 26 (Monday) that it would shoot for an IPO valuation of $1.5 billion, offering over 25 million shares in the range of $14 and $17.

But is Honest stock more of a buy today than it was then?


This COVID-19 Vaccine Stock Has More Upside Than Pfizer or Moderna

Developing effective vaccines against a deadly global pandemic is certainly bullish for a stock.

Indeed, Moderna and Pfizer shareholders have put away as much as 516% and 51% gains, respectively.

And when a lot of investors see this, they fear they’ve missed out.

Well, Michael’s here to assure you that you haven’t; not by a long shot.

And today, he’s got a vaccine stock you should put at the top of your “must-buy” list for the week ahead… .


Trading Strategies

Why the Dow Jones Could Quickly Hit 35,000

The anticipation is palpable… and building fast. We've had three reports on extremely effective upcoming coronavirus vaccines, and each report practically blows the last one out of the water.

First we heard preliminary reports that Pfizer and BioNTech's revolutionary messenger RNA (mRNA) coronavirus vaccine was 90% effective. That was great… until yesterday morning, when the biotechs got back in touch to say the real figure was something closer to 95%. And in the middle, we've heard from Moderna, which is reporting its mRNA vaccine is 94.5% effective.

Every time, stocks have taken off like a shot at the news; vaccines have helped push the Dow back above its February 2020 highs.

Here's the thing… setting aside the six vaccines The New York Times reports are in limited use in China and Russia – about which there are many unanswered questions – there are at least nine more coronavirus vaccines deep in phase 3, large-scale efficacy trials.

And there are no less than 55 more candidates in earlier, phase 1 and 2 trials. Some of these vaccine candidates won't advance, but others almost certainly will – two have already.

That all this has happened in less than a year is an "Apollo moonshot"-like scientific achievement. But that's also a whole lot of concentrated upside potential that could flood the markets and push stocks to almost unthinkable highs.

So I asked Money Morning Chief Investment Strategist Shah Gilani what it all means for us investors…


Dow Jones

Dow Jones Today Could Take a Dip on Fresh Earnings Reports

The Dow Jones today is down on the first major day of Q3 earnings reports.

Investors also await updates from Washington on a potential stimulus plan.

Markets remain in a holding pattern as Congress and the Trump administration continue to haggle over the size of a new deal.

Trump has said that he will approve a deal worth $1.8 trillion.

Democrats are hoping for a larger plan before the election.